Browsing: Weight Loss

July 20, 2026 – Adolescents and young adults in the U.S. are increasingly using popular GLP-1 weight-loss drugs alone or in conjunction with metabolic and bariatric surgery (MBS) to manage obesity, according to a study by UT Southwestern Medical Center researchers published in JAMA Pediatrics

HealthDay News — For children and adolescents with attention-deficit/hyperactivity disorder (ADHD), comparable, significant symptom improvement is seen with dexamphetamine and methylphenidate, but weight loss is greater with dexamphetamine at three months, according to a study published online July 7 in the Journal of Paediatrics and Child Health

July 20, 2026 ByMaureen Salamon, Executive Editor, Harvard Women’s Health Watch

Novo Nordisk NVO received a meaningful commercial boost last week after the European Commission approved the oral version of Wegovy (semaglutide 25 mg) for adults with obesity and at least one weight-related comorbidity. The approval expands the company’s obesity franchise across Europe, making Wegovy the first GLP-1 tablet approved for weight management in the EU and…

Novo Nordisk stock is trading close to record territory, with investors focusing on how sustained demand for its obesity and diabetes drugs is feeding through into revenue and profit growth for the Danish pharmaceutical group (ISIN DK0062498333). According to the companys most recent quarterly report for Q1 2025, Novo Nordisk reported revenue of DKK 108.0…

For decades, obesity has posed one of the most formidable threats to public health. Individuals living with obesity are at heightened risk of myriad co-morbid conditions, ranging from cardiovascular disease and type 2 diabetes to certain cancers. Given the expansive health implications of obesity, its prevention and treatment are critical to improving population health outcomes.…

Even with the rise of GLP-1-based drugs, bariatric weight-loss surgery remains an effective intervention for many people living with obesity. But does everyone benefit from the surgery equally?

(Catch all the Business News, Breaking News, and Latest News Updates on The Economic Times.)

GLP-1 medications have garnered global interest for their benefits in weight loss and diabetes management. Growing consumer access to these products is driving innovations in the food and nutrition industries for healthier, nutrient-dense options in smaller portion sizes. 

Two studies, presented recently at the International Congress on Obesity (ICO 2026) – the global congress organised by the World Obesity Federation in Mexico City – shed light on an aspect of the obesity pandemic that goes far beyond willpower. At the heart of it all is the way in which our bodies are literally…